Sfoglia per AUTORE
ORIOL A
Collezione AOU Città della Salute di Torino

  

Items : 10

Daratumumab or Active Monitoring for High-Risk Smoldering Multiple Myeloma. in The New England journal of medicine / N Engl J Med. 2024 Dec 9. doi: 10.1056/NEJMoa2409029.
2024
AOU Città della Salute di Torino

Dimopoulos MA; Voorhees PM; Schjesvold F; Cohen YC; Hungria V; Sandhu I; Lindsay J; Baker RI; Suzuki K; Kosugi H; Levin MD; Beksac M; Stockerl-Goldstein K; Oriol A; Mikala G; Garate G; Theunissen K; Spicka I; Mylin AK; Bringhen S; Uttervall K; Pula B; Medvedova E; Cowan AJ; Moreau P; Mateos MV; Goldschmidt H; Ahmadi T; Sha L; et alii...

2023
AOU Città della Salute di Torino

Dimopoulos MA; Terpos E; Boccadoro M; Delimpasi S; Beksac M; Katodritou E; Moreau P; Baldini L; Symeonidis A; Bila J; Oriol A; Mateos MV; Einsele H; Orfanidis I; Kampfenkel T; Liu W; Wang J; Kosh M; Tran N; Carson R; Sonneveld P;

Pomalidomide, bortezomib, and dexamethasone at first relapse in lenalidomide-pretreated myeloma: A subanalysis of OPTIMISMM by clinical characteristics. in European journal of haematology / Eur J Haematol. 2022 Jan;108(1):73-83. doi: 10.1111/ejh.13706. Epub 2021 Sep 22.
2022
AOU Città della Salute di Torino

Larocca A; Yagci M; Robak P; Liberati AM; Galli M; Lindsay J; Oriol A; Beksac M; Salomo M; Pavic M; Dürig J; Jenner M; Corso A; Engelhardt M; Sonneveld P; Rodriguez-Otero P; White D; Anderson LD Jr; Moreau P; Weisel K; Schjesvold F; Richardson PG; Vural F; Kanate AS; Jiang R; Grote L; Peluso T; Dimopoulos M;

Patient-reported outcomes in relapsed/refractory multiple myeloma treated with melflufen plus dexamethasone: analyses from the Phase II HORIZON study. in British journal of haematology / Br J Haematol. 2022 Feb;196(3):639-648. doi: 10.1111/bjh.17887. Epub 2021 Oct 21.
2022
AOU Città della Salute di Torino

Laubach J; Nadeem O; Mazumder A; Raptis A; Rodriguez-Otero P; Oriol A; Alegre A; Cavo M; Maisel C; Mateos MV; Paner A; Bladé J; Touzeau C; Leleu X; Larocca A; Sandberg A; Orre M; Torrång A; Bakker NA; Richardson PG;

Melflufen and Dexamethasone in Heavily Pretreated Relapsed and Refractory Multiple Myeloma. in Journal of clinical oncology : official journal of the American Society of Clinical Oncology / J Clin Oncol. 2021 Mar 1;39(7):757-767. doi: 10.1200/JCO.20.02259. Epub 2020 Dec 9.
2021
AOU Città della Salute di Torino

Laubach JP; Moreb JS; Anderson KC; Raptis A; Mazumder A; Maisel C; Paner A; Alegre A; Hassoun H; Touzeau C; Hiemenz JW; Nadeem O; Leleu X; Rodriguez-Otero P; Cavo M; Bladé J; Larocca A; Oriol A; Richardson PG; Thuresson S; Thuresson M; Byrne C; Harmenberg J; Bakker NA; Mateos MV;

Melflufen for relapsed and refractory multiple myeloma. in Expert opinion on investigational drugs / Expert Opin Investig Drugs. 2020 Oct;29(10):1069-1078. doi: 10.1080/13543784.2020.1808884. Epub 2020
2020
AOU Città della Salute di Torino

Oriol A; Larocca A; Leleu X; Hajek R; Hassoun H; Rodríguez-Otero P; Paner A; Schjesvold FH; Gullbo J; Richardson PG;

Ixazomib as Postinduction Maintenance for Patients With Newly Diagnosed Multiple Myeloma Not Undergoing Autologous Stem Cell Transplantation: The Phase III TOURMALINE-MM4 Trial. in Journal of clinical oncology : official journal of the American Society of Clinical Oncology / J Clin Oncol. 2020 Dec 1;38(34):4030-4041. doi: 10.1200/JCO.20.02060. Epub 2020 Oct 6.
2020
AOU Città della Salute di Torino

Labotka R; Vorog A; Morgan G; Mateos MV; Iida S; Leleu X; Katodritou E; Chng WJ; Beksac M; Bringhen S; Garg M; Hájek R; Oriol A; Quach H; Špi?ka I; Dimopoulos MA; Wang B; Palumbo A; Lonial S;

Pembrolizumab plus pomalidomide and dexamethasone for patients with relapsed or refractory multiple myeloma (KEYNOTE-183): a randomised, open-label, phase 3 trial. in The Lancet. Haematology / Lancet Haematol. 2019 Sep;6(9):e459-e469. doi: 10.1016/S2352-3026(19)30110-3. Epub 2019 Jul 18.
2019
AOU Città della Salute di Torino

Mateos MV; Blacklock H; Schjesvold F; Oriol A; Simpson D; George A; Goldschmidt H; Larocca A; Chanan-Khan A; Sherbenou D; Avivi I; Benyamini N; Iida S; Matsumoto M; Suzuki K; Ribrag V; Usmani SZ; Jagannath S; Ocio EM; Rodriguez-Otero P; San Miguel J; Kher U; Farooqui M; Liao J; Marinello P; Lonial S;

Phase 2 study of tabalumab, a human anti-B-cell activating factor antibody, with bortezomib and dexamethasone in patients with previously treated multiple myeloma. in British journal of haematology / Br J Haematol. 2017 Mar;176(5):783-795. doi: 10.1111/bjh.14483. Epub 2016 Dec 22.
2017
AOU Città della Salute di Torino

Kaiser CJ; Conti I; Tai DF; Wooldridge JE; Kuliczkowski K; Beksac M; Huang SY; Oriol A; Holstein SA; Grz??ko N; Benboubker L; Terpos E; Raje NS; Moreau P; Nguyen TS; Cronier DM; Palumbo A;

Age and organ damage correlate with poor survival in myeloma patients: meta-analysis of 1435 individual patient data from 4 randomized trials. in Haematologica / Haematologica. 2013 Jun;98(6):980-7. doi: 10.3324/haematol.2012.075051. Epub 2013 Feb 26.
2013
AOU Città della Salute di Torino

Bringhen S; Mateos MV; Zweegman S; Larocca A; Falcone AP; Oriol A; Rossi D; Cavalli M; Wijermans P; Ria R; Offidani M; Lahuerta JJ; Liberati AM; Mina R; Callea V; Schaafsma M; Cerrato C; Marasca R; Franceschini L; Evangelista A; Teruel AI; van der Holt B; Montefusco V; Ciccone G; Boccadoro M; San Miguel J; Sonneveld P; Palumbo A;